ARTICLE | Finance
Galapagos spinout Coultreon draws $125M to test SIK3 inhibitor: Venture Report
Plus: Pair of European microbiome companies draw rounds; Apuri backs Sigmeta; and more
April 30, 2026 9:39 PM UTC
A Belgian company set up to develop an immunology program spun out from Galapagos has raised a $125 million series A round to advance the therapy in multiple indications.
A syndicate led by Sofinnova Investments backed Coultreon Biopharma B.V. as it tests oral SIK3 inhibitor COL-5671 in a Phase I trial. The start-up’s development program for the molecule includes planned Phase II proof-of-concept trials in psoriasis and ulcerative colitis, with data potentially due in 2027...